Investing.com - TD Cowen initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with a Buy rating on Wednesday, citing the potential of the company’s telitacicept therapy. The stock, currently trading ...
Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...
Optical remote sensing technologies provide the ability to monitor short- and long-term changes in coral reefs, deep-sea fisheries, and off-shore oilfields, and to supply real-time information about ...
Vor Biopharma's estimated fair value is US$15.10 based on 2 Stage Free Cash Flow to Equity Vor Biopharma is estimated to be 49% undervalued based on current share price of US$7.68 Our fair value ...
Make sure not to miss this valuable item your first time around. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Add us as a preferred source on ...
Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share. The gross proceeds from the offering are expected to be $100 million. In ...
China biotech RemeGen and its new U.S. partner Vor Bio are on a roll with their first-in-class autoimmune treatment telitacicept. Two weeks after RemeGen revealed the success of a China phase 3 trial ...
Hosted on MSN
Trying a VOR Instrument Approach!
I love being a licensed private pilot. As you may have seen from other videos, I am starting my instrument rating training. I really believe that I will be a much safer pilot when I get my IFR or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback